The adjuvanted recombinant zoster vaccine (RZV; Shingrix, GSK) for shingles provides long-term protection against herpes zoster (HZ) for up to 10 years after vaccination.
The data analysis was completed after at least four years of follow-up, spanning up to 10 years following initial vaccination, according to data presented at IDWeek 2022, held in Washington, D.C. (poster 11).
“The primary objective of the year 4 interim analysis was to determine the vaccine efficacy against